Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Department of Public Health and Preventive Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Acta Dermatovenerol Alp Pannonica Adriat. 2023 Jun;32(2):41-47.
The use of postbiotics, which are defined as dead microorganisms and/or their components that provide health benefits to the target host, has been shown to reduce the severity of atopic dermatitis (AD) in several studies.
A systematic literature review was conducted in Pubmed, the Cochrane Library, Science Direct, Clinicaltrials.gov, and Google Scholar, covering the period from January 2012 to July 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. AD patients of all ages that received oral postbiotics or placebo as treatment were the focus of the study. The main study outcome was the scoring of atopic dermatitis (SCORAD) and other measures, such as extension area, disease intensity, and adverse events. The final data were pooled using a fixed-effect model.
A meta-analysis of three studies found that, compared to placebo, SCORAD was lower in subjects that were given oral postbiotics from Lactobacillus sp. (mean difference: -2.90, 95% confidence interval [CI; -4.21, -1.59], p < 0.00001). From the comparison of two studies, the differences in disease extension (mean difference: -2.40, 95% CI [-7.67, 2.81], p = 0.37) and intensity (mean difference: -0.27, 95% CI [-0.84, 0.30], p = 0.36) were not significant.
The administration of oral postbiotics from Lactobacillus sp. has the potential to alleviate the severity of AD as indicated by a reduction in SCORAD scores.
后生元，定义为提供目标宿主健康益处的死微生物及其成分，已在多项研究中显示可降低特应性皮炎（AD）的严重程度。
按照系统评价和荟萃分析报告的首选条目（PRISMA）指南，在 Pubmed、Cochrane 图书馆、Science Direct、Clinicaltrials.gov 和 Google Scholar 中进行了系统文献回顾，涵盖了 2012 年 1 月至 2022 年 7 月的时期。研究对象为接受口服后生元和安慰剂治疗的所有年龄段的 AD 患者。主要研究结果是特应性皮炎评分（SCORAD）和其他措施，如扩展面积、疾病强度和不良事件。使用固定效应模型对最终数据进行汇总。
对 3 项研究的荟萃分析发现，与安慰剂相比，口服乳杆菌属后生元治疗的受试者的 SCORAD 较低（平均差异：-2.90，95%置信区间 [CI]：-4.21，-1.59]，p < 0.00001）。从两项研究的比较来看，疾病扩展（平均差异：-2.40，95%CI[-7.67，2.81]，p = 0.37）和强度（平均差异：-0.27，95%CI[-0.84，0.30]，p = 0.36）差异无统计学意义。
口服乳杆菌属后生元的给药有可能减轻 AD 的严重程度，表现为 SCORAD 评分降低。
